Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Grainne O’Kane: CheckMate 9DW expanded analyses in HCC - OncoDaily
CHC: primeros resultados del estudio CheckMate 9DW con nivolumab ...
CheckMate 9DW Breakthrough: Nivolumab and Ipilimumab Show Promise as ...
CheckMate 9DW Study Results and Use of Ipiimumab/Nivolumab in First ...
CheckMate 9DW Expanded Analyses: Nivo/Ipi Versus Len/Sor as 1L Therapy ...
CheckMate 9DW: Ipi/Nivo as First-Line Treatment for uHCC | GI Oncology Now
孙惠川教授：CheckMate 9DW 研究扩展分析结果重磅发布，O+Y 方案再证长生存获益丨2025 ASCO GI_腾讯新闻
Neue Erstlinientherapie bei inoperablem Leberzellkarzinom: CheckMate ...
CheckMate 8HW Trial at ASCO 2025: Nivolumab Plus Ipilimumab Sets New ...
切除不能肝細胞がん1次治療としてのニボルマブ＋イピリムマブvs.レンバチニブまたはソラフェニブ、アジア人解析結果（CheckMate 9DW ...
FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of ...
eCase - Tx of Advanced HCC | CCO
Angela Lamarca: Update form CHECKMATE-9DW trial in HCC - Asian ...
Advancing First-Line Therapy for Unresectable Hepatocellular Carcinoma ...
FDA Approves Nivolumab and Ipilimumab as First-Line Treatment for ...
Nivolumab Plus Ipilimumab Shows Promise as First-Line Treatment for ...
First-Line Nivolumab/Ipilimumab Improves Survival in Unresectable ...
Safety Profile of Nivolumab Plus Ipilimumab Combination Therapy in ...
An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC ...
ASCO GU 2021: Patient-Reported Outcomes Of Patients With Advanced Renal ...
Cáncer de hígado avanzado: nivolumab más ipilimumab cumplen con el ...
CheckMate-9DW trial evaluating Opdivo (nivolumab) + Yervoy (ipilimumab ...
First-Line Nivolumab Plus Ipilimumab Could Become New Standard Care for ...
盛锡楠教授：转移性肾癌BIONIKK、CheckMate 9ER研究——免疫和靶向，并排走还是前后走丨瞭望FM·ESMO特辑_治疗
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line ...
First-line nivolumab plus ipilimumab combined with two cycles of ...
Opdivo (Nivolumab Injection): Side Effects, Uses, Dosage, Interactions ...
LBA 4008 Annual Meeting of the American Society of Clinical Oncology ...
EMA Validates Application for Nivolumab/Ipilimumab in Liver Cancer Type
【ASCO 2024】洞察诊疗前沿，看晚期HCC免疫联合治疗新进展-MedSci.cn
ASCO GU 2023: Nivolumab plus Cabozantinib vs Sunitinib for First-Line ...
2025 ESMO GI|秦叔逵教授：CheckMate-9DW中国人群扩展分析揭晓，O+Y以循证力量驱动中国HCC一线治疗变革医药新闻 ...
EIKCS 2022: Nivolumab + Ipilimumab + Cabozantinib for Previously ...
First-line nivolumab-ipilimumab therapy extends survival in unresected ...
Nivolumab Plus Ipilimumab Improves OS and Response in Frontline uHCC
Efficacy Data Support Nivolumab/Ipilimumab as First-Line HCC Treatment
FDA OKs Nivolumab/Ipilimumab in Unresectable/Metastatic HCC
Frontline nivolumab plus ipilimumab ups OS, ORR in patients with uHCC ...
00403-9/asset/06c0bccf-4414-4138-b9f7-8810aac58258/main.assets/gr2.jpg)
00403-9/asset/7648f1d3-f123-4d52-92bf-a2fd5ccdbd5d/main.assets/gr3.jpg)
